{"product_id":"vcyt-vrio-analysis","title":"Veracyte, Inc. (VCYT): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the secrets to Veracyte, Inc. (VCYT)'s market staying power with this focused VRIO Analysis! We distill whether their key assets are truly Valuable, Rare, Inimitable, and Organized enough to secure a lasting competitive advantage. Dive in now to see the precise strengths - or weaknesses - that define their current and future success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e1. Decipher Prostate Market Leadership\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at the core engine of Veracyte, Inc.'s recent success, and the numbers from the third quarter of 2025 defintely back it up. The Decipher prostate test is driving serious top-line growth, which is exactly what we want to see from a market leader. For the three months ended September 30, 2025, Decipher revenue hit \u003cstrong\u003e$82.2 million\u003c\/strong\u003e, marking a \u003cstrong\u003e26%\u003c\/strong\u003e year-over-year increase. That's not just a good quarter; it's the \u003cstrong\u003e14th consecutive quarter\u003c\/strong\u003e of over \u003cstrong\u003e25%\u003c\/strong\u003e volume growth for Decipher.\u003c\/p\u003e\n\u003cp\u003eThis performance isn't accidental; it's built on a foundation that competitors can't easily copy. The Rarity and high Imitability barrier comes from the sheer weight of clinical proof. Think about it: deep clinical validation and established use in the physician's workflow for a major cancer type like prostate cancer creates a significant moat. They aren't just selling a test; they are selling a standard of care supported by data.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at how that evidence base stacks up right now:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDecipher volume grew \u003cstrong\u003e26%\u003c\/strong\u003e to about \u003cstrong\u003e26,700 tests\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eManagement presented \u003cstrong\u003e23 new abstracts\u003c\/strong\u003e across Decipher and GRID in Q3 alone.\u003c\/li\u003e\n\u003cli\u003eNew data from the BALANCE trial shows a Decipher-enabled biomarker predicts hormone therapy benefit.\u003c\/li\u003e\n\u003cli\u003eThe company is already planning to build on this with new signatures like PORTOS and PTEN in 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe VRIO assessment for this specific market leadership position looks strong:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Implication\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$82.2 million\u003c\/strong\u003e in Q3 2025 revenue; \u003cstrong\u003e26%\u003c\/strong\u003e YoY growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh\u003c\/td\u003e\n\u003ctd\u003eDeep clinical validation and established NCCN risk category adoption.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\u003c\/td\u003e\n\u003ctd\u003eLong clinical trial cycles and reimbursement hurdles for competitors to match the evidence base.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eManagement explicitly leverages momentum for pipeline expansion, like the upcoming TrueMRD launch.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Organization component is solid because management is actively using this momentum to fuel the next wave of growth. They aren't just resting on the current success; they are using the data moat to support pipeline expansion, including the expected launch of TrueMRD. So, the Competitive Advantage here is \u003cstrong\u003eSustained\u003c\/strong\u003e. The established clinical workflow and the sheer volume of supporting data act as a powerful barrier, protecting this key revenue stream for the foreseeable future.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e2. Afirma Franchise Stability\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a reliable, recurring revenue base, contributing \u003cstrong\u003e$43.2 million\u003c\/strong\u003e in Q3 2025 testing revenue.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e7%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma Volume\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e17,000\u003c\/strong\u003e tests\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e13%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Testing Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$127.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e17%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Testing Volume\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e43,679\u003c\/strong\u003e tests\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e19%\u003c\/strong\u003e growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; other companies have thyroid nodule tests, but Afirma has deep installed base trust.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; the brand equity and existing reimbursement pathways are costly and time-consuming to copy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Effective; the team manages to grow this mature product line by \u003cstrong\u003e7%\u003c\/strong\u003e year-over-year in Q3 2025.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAfirma volume growth was \u003cstrong\u003e13%\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe company supported the presentation of \u003cstrong\u003e12\u003c\/strong\u003e Afirma-related abstracts at the 2025 American Thyroid Association meeting.\u003c\/li\u003e\n\u003cli\u003eThe transition of Afirma to the v2 Veracyte transcriptome is enabling COGS reduction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it will erode over time unless continually refreshed with new technology.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e3. Veracyte Diagnostics Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe Veracyte Diagnostics Platform acts as the central nervous system, integrating genomic data, bioinformatics, and AI to create high-performing tests.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The platform underpins significant financial performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFull Year 2024 Total Revenue reached \u003cstrong\u003e$445.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull Year 2024 Testing Revenue was \u003cstrong\u003e$419.0 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDecipher volume grew by \u003cstrong\u003e36%\u003c\/strong\u003e in Full Year 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; a truly integrated platform that connects data inputs to clinical outputs is rare in the fragmented diagnostics field.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very difficult; it requires deep, cross-functional expertise in genomics, software engineering, and clinical science.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Well-organized; this platform underpins their ability to raise 2025 revenue guidance multiple times.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFull Year 2025 Testing Revenue guidance was raised to a range of \u003cstrong\u003e$484 million to $487 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA margin reached \u003cstrong\u003e30%\u003c\/strong\u003e in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe platform's output demonstrates tangible clinical and commercial success:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Result\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Result\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e$115.9 million\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$131.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting Revenue\u003c\/td\u003e\n\u003ctd\u003e$109.5 million\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$127.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher Revenue\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$82.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma Revenue\u003c\/td\u003e\n\u003ctd\u003eNot explicitly stated\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher Volume (Approx.)\u003c\/td\u003e\n\u003ctd\u003eApproximately 21,250 tests\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e26,700 tests\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDecipher volume achieved its thirteenth consecutive quarter of over \u003cstrong\u003e25%\u003c\/strong\u003e year-over-year volume growth in Q2 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this technological backbone is a core differentiator for future innovation.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDecipher Prostate test received a \u003cstrong\u003elevel 1b\u003c\/strong\u003e evidence rating in NCCN guidelines.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e4. Proprietary Genomic and Clinical Data Assets\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Fuels the platform, improving test accuracy and supporting claims for guideline inclusion, which is key to payer coverage.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe proprietary data assets directly support the evidence generation engine, leading to guideline inclusion and payer coverage, which drives revenue. For the full year 2024, Veracyte generated testing revenue of \u003cstrong\u003e$419.0 million\u003c\/strong\u003e from a total testing volume of \u003cstrong\u003e142,925 tests\u003c\/strong\u003e. The Decipher Prostate test achieved the highest-level rating among gene expression tests in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer, version V1.2025, published in December 2024. Furthermore, coverage for the Decipher Prostate test was secured with one of the largest commercial payers in the U.S., covering close to \u003cstrong\u003e30 million members\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: High; the sheer volume of de-identified patient data linked to outcomes is a unique asset built over years.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe cumulative number of patients tested across key franchises represents the scale of the proprietary dataset. As of early 2025, Decipher has tested over \u003cstrong\u003e275,000 patients\u003c\/strong\u003e, and Afirma has tested more than \u003cstrong\u003e350,000 patients\u003c\/strong\u003e. A study linking Decipher data to the National Cancer Institute's SEER database underscores the depth of outcome linkage. Full year 2024 total volume reached \u003cstrong\u003e152,750 tests\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Very difficult; data acquisition is slow, expensive, and requires patient consent and ethical oversight.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe historical nature of data accumulation, combined with the necessary ethical and regulatory frameworks for linking genomic data to clinical outcomes, creates a significant barrier to entry. The platform has demonstrated consistent volume growth, with testing revenue growing \u003cstrong\u003e28%\u003c\/strong\u003e year-over-year for the full year 2024.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: Leveraged; new insights from this data support upcoming launches like Prosigna LDT.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe data platform is being leveraged to launch new tests, such as the Prosigna Breast Cancer Assay as a Laboratory Developed Test (LDT) in the U.S., planned for mid-\u003cstrong\u003e2026\u003c\/strong\u003e. This test targets approximately \u003cstrong\u003e225,000\u003c\/strong\u003e early-stage hormone receptor positive breast cancer patients annually in the US. Data from Prosigna in a Norway study showed that its use changed adjuvant therapy decisions for almost \u003cstrong\u003eone-third (29%)\u003c\/strong\u003e of patients, with \u003cstrong\u003e45%\u003c\/strong\u003e of those initially slated for chemotherapy being de-escalated.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; data network effects mean more tests generate better data, which attracts more users.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe continuous cycle of testing generating data, which in turn strengthens evidence for guideline inclusion and reimbursement, creates a self-reinforcing competitive moat. For example, Decipher volume grew \u003cstrong\u003e36%\u003c\/strong\u003e in full year 2024 to more than \u003cstrong\u003e80,000 tests\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Testing Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$419.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Testing Volume\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e142,925 tests\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher Volume\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e80,000 tests\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma Volume\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e60,000 tests\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Decipher Patients Tested\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e275,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of early 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCumulative Afirma Patients Tested\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e350,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eAs of early 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNCCN Guideline Inclusion\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eHighest-level rating\u003c\/strong\u003e for Decipher Prostate\u003c\/td\u003e\n\u003ctd\u003eV1.2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial Payer Coverage\u003c\/td\u003e\n\u003ctd\u003eClose to \u003cstrong\u003e30 million members\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eFor Decipher Prostate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eProsigna LDT Target Market Size:\u003c\/strong\u003e Approximately \u003cstrong\u003e300,000\u003c\/strong\u003e patients diagnosed annually with breast cancer in the US.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eProsigna Treatment Decision Change Rate:\u003c\/strong\u003e Changed adjuvant therapy decisions for almost \u003cstrong\u003e29%\u003c\/strong\u003e of patients in a Norway study.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eProsigna Chemotherapy De-escalation Rate:\u003c\/strong\u003e \u003cstrong\u003e45%\u003c\/strong\u003e of patients assigned chemotherapy were de-escalated to endocrine therapy after Prosigna results.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e5. Evidence-Generation Engine\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This systematic process turns test results into high-quality evidence, which is crucial for securing durable reimbursement and inclusion in clinical guidelines.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; many labs generate data, but few have a dedicated, successful engine for formal evidence generation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; it requires dedicated medical affairs, regulatory know-how, and successful publication strategies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Focused; management cites this engine as reinforcing the value of their tests.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; guideline inclusion creates a high barrier to entry for new competitors.\u003c\/p\u003e\n\u003cp\u003eThe engine's output directly supports market access and test adoption, as evidenced by recent guideline inclusions and publication activity:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe \u003cstrong\u003eDecipher Prostate Genomic Classifier (GC)\u003c\/strong\u003e secured its position as the only gene expression test included in \u003cstrong\u003eV1. 2025\u003c\/strong\u003e of the \u003cstrong\u003eNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)\u003c\/strong\u003e for Prostate Cancer, published in \u003cstrong\u003eDecember 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe \u003cstrong\u003eDecipher Prostate test\u003c\/strong\u003e received the highest-level rating among gene expression tests in updated \u003cstrong\u003eNCCN prostate cancer guidelines\u003c\/strong\u003e (as of Q2 2024).\u003c\/li\u003e\n\u003cli\u003eThe company announced \u003cstrong\u003e17 Decipher-focused abstracts\u003c\/strong\u003e to be presented at the \u003cstrong\u003e2025 ASCO GU Symposium\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eData published online in \u003cstrong\u003eCell\u003c\/strong\u003e from the \u003cstrong\u003eSTAMPEDE trial\u003c\/strong\u003e showed that the \u003cstrong\u003eDecipher Prostate Genomic Classifier\u003c\/strong\u003e predicts chemotherapy benefit in patients with metastatic prostate cancer.\u003c\/li\u003e\n\u003cli\u003eIn Q2 2024, the company reinforced its commitment to evidence expansion with \u003cstrong\u003ethree published Decipher Prostate test studies\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eIn Q3 2025, the company supported the presentation of \u003cstrong\u003etwelve abstracts\u003c\/strong\u003e covering clinical \u003cstrong\u003eAfirma GSC data\u003c\/strong\u003e and research with \u003cstrong\u003eAfirma GRID\u003c\/strong\u003e at the \u003cstrong\u003e2025 American Thyroid Association Annual Meeting\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eHistorical reimbursement success includes achieving Medicare pricing stability for \u003cstrong\u003eAfirma\u003c\/strong\u003e in \u003cstrong\u003eJanuary 2018\u003c\/strong\u003e, resulting in an increased reimbursement rate of approximately \u003cstrong\u003e$3,600 per test\u003c\/strong\u003e from approximately \u003cstrong\u003e$3,200 per test\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe financial performance of key tests reflects the impact of this evidence generation:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eTest\/Period\u003c\/td\u003e\n\u003ctd\u003eValue\/Amount\u003c\/td\u003e\n\u003ctd\u003eContext\/Comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eDecipher (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$82.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e26%\u003c\/strong\u003e year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume\u003c\/td\u003e\n\u003ctd\u003eDecipher (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e26,700 tests\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e26%\u003c\/strong\u003e year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eAfirma (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e7%\u003c\/strong\u003e year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVolume\u003c\/td\u003e\n\u003ctd\u003eAfirma (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e17,000 tests\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e13%\u003c\/strong\u003e year-over-year.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting Revenue Growth Guidance (2025)\u003c\/td\u003e\n\u003ctd\u003eTotal Testing Revenue\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003ctd\u003eRaised from prior guidance of approximately \u003cstrong\u003e12% to 15%\u003c\/strong\u003e growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting Volume Growth (Full Year 2024)\u003c\/td\u003e\n\u003ctd\u003eDecipher\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e36%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGrew to more than \u003cstrong\u003e80,000 tests\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesting Revenue Growth (Full Year 2024)\u003c\/td\u003e\n\u003ctd\u003eDecipher\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e43%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear-over-year growth.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe platform's capabilities are cited as fueling durable reimbursement and guideline inclusion:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform Component\u003c\/td\u003e\n\u003ctd\u003eRecent Activity\/Output\u003c\/td\u003e\n\u003ctd\u003eFinancial Implication\/Metric\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVeracyte Diagnostics Platform\u003c\/td\u003e\n\u003ctd\u003eReceived \u003cstrong\u003eMolDx\u003c\/strong\u003e approval for \u003cstrong\u003eDecipher\u003c\/strong\u003e technical assessment submission in metastatic population.\u003c\/td\u003e\n\u003ctd\u003eSupports durable reimbursement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvidence Generation Engine\u003c\/td\u003e\n\u003ctd\u003eDrives durable reimbursement and guideline inclusion.\u003c\/td\u003e\n\u003ctd\u003eUnderpins testing revenue growth of \u003cstrong\u003e17%\u003c\/strong\u003e in Q3 2025 testing revenue ($127.8 million).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher\u003c\/td\u003e\n\u003ctd\u003eAchieved its \u003cstrong\u003ethirteenth consecutive quarter\u003c\/strong\u003e of over \u003cstrong\u003e25%\u003c\/strong\u003e year-over-year volume growth (as of Q2 2025).\u003c\/td\u003e\n\u003ctd\u003eTesting ASP for total tests in Q2 2025 was \u003cstrong\u003e$2,881\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e6. Robust Balance Sheet and Liquidity\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the financial cushion to fund R\u0026amp;D, absorb unexpected costs (like the SAS deconsolidation), and pursue strategic M\u0026amp;A.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while many firms have cash, Veracyte ended Q3 2025 with \u003cstrong\u003e$366.4 million\u003c\/strong\u003e in cash, a strong position for its size.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy, but requires time; competitors can raise capital, but this level of liquidity was earned through operational discipline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Prudent; they generated \u003cstrong\u003e$44.8 million\u003c\/strong\u003e in cash from operations in Q3 2025 alone.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; cash can be spent, but the current strength allows for aggressive near-term moves.\u003c\/p\u003e\n\n\u003ch3\u003eKey Balance Sheet and Liquidity Metrics (As of Q3 2025 or TTM)\u003c\/h3\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, \u0026amp; Short-Term Investments (Q3 End)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$366.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow from Operations (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow from Operations (Last Twelve Months - TTM)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$108.25 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.37 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$110.12 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt (Latest Reported)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40.45 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$325.98 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shareholder Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.3 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe balance sheet strength supports strategic flexibility, evidenced by the ability to generate significant operating cash flow while maintaining a substantial cash reserve.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGAAP Net Income for Q3 2025 was \u003cstrong\u003e$19.1 million\u003c\/strong\u003e, representing \u003cstrong\u003e15%\u003c\/strong\u003e of revenue.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA for Q3 2025 was \u003cstrong\u003e$39.7 million\u003c\/strong\u003e, or \u003cstrong\u003e30%\u003c\/strong\u003e of revenue.\u003c\/li\u003e\n\u003cli\u003eTotal Current Assets were \u003cstrong\u003e$449.22 million\u003c\/strong\u003e, significantly exceeding Short Term Liabilities of \u003cstrong\u003e$72.2 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company raised its full-year 2025 total revenue guidance to \u003cstrong\u003e$506 million\u003c\/strong\u003e to \u003cstrong\u003e$510 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e7. Broad Multi-Indication Portfolio Coverage\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Diversifies risk away from any single cancer type, covering thyroid, prostate, breast, bladder cancers, and ILD.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication Area\u003c\/th\u003e\n\u003cth\u003eProduct(s)\u003c\/th\u003e\n\u003cth\u003eRelevant Metric\/Data Point\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eThyroid Cancer\u003c\/td\u003e\n\u003ctd\u003eAfirma Genomic Sequencing Classifier\u003c\/td\u003e\n\u003ctd\u003eAfirma volume grew \u003cstrong\u003e8%\u003c\/strong\u003e in Q4 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProstate Cancer\u003c\/td\u003e\n\u003ctd\u003eDecipher Prostate Genomic Classifier\u003c\/td\u003e\n\u003ctd\u003eDecipher revenue grew \u003cstrong\u003e44%\u003c\/strong\u003e in Q4 2024; volume grew \u003cstrong\u003e45%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLung Cancer\u003c\/td\u003e\n\u003ctd\u003ePercepta Nasal Swab test\u003c\/td\u003e\n\u003ctd\u003eDesigned to assess lung cancer risk in patients with lung nodules.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBreast Cancer\u003c\/td\u003e\n\u003ctd\u003eProsigna breast cancer test\u003c\/td\u003e\n\u003ctd\u003eAssesses risk of recurrence for certain types of early-stage breast cancer.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterstitial Lung Disease (ILD)\u003c\/td\u003e\n\u003ctd\u003eEnvisia Genomic Classifier\u003c\/td\u003e\n\u003ctd\u003eIPF diagnosis increased by \u003cstrong\u003e39%\u003c\/strong\u003e post-Envisia in one study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eIn a study of ILD patients, physician confidence in diagnosis increased from \u003cstrong\u003e5.8%\u003c\/strong\u003e pre-Envisia to \u003cstrong\u003e42%\u003c\/strong\u003e post-Envisia. The recommendation for anti-fibrotic drug use increased from \u003cstrong\u003e11.9%\u003c\/strong\u003e to \u003cstrong\u003e71.4%\u003c\/strong\u003e following an Envisia-positive result for UIP.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; a few large players cover this breadth, but Veracyte has deep focus within each niche. The portfolio commercially covers at least five distinct disease areas including thyroid, prostate, breast, lung cancers, and ILD.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; building expertise and regulatory approval across this many distinct disease areas takes significant time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strategic; they aim to cover the care continuum in multiple indications. Full year 2024 total revenue reached \u003cstrong\u003e$445.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; this breadth allows for cross-selling and platform leverage across different physician groups. Total testing revenue for the full year 2024 was \u003cstrong\u003e$419.0 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e8. IVD Services and Manufacturing Capabilities\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eValue: Offers a secondary, non-testing revenue stream by providing manufacturing, quality control, and process transfer to biopharma partners.\u003c\/li\u003e\n\u003cli\u003eRarity: Moderate; this capability is often outsourced, so having in-house expertise is a niche advantage.\u003c\/li\u003e\n\u003cli\u003eImitability: Moderate; establishing GMP-compliant facilities and quality systems is a known, but high-cost, barrier.\u003c\/li\u003e\n\u003cli\u003eOrganization: Utilized; this business line was part of the deconsolidated SAS entity, suggesting a strategic streamlining to focus on core testing.\u003c\/li\u003e\n\u003cli\u003eCompetitive Advantage: Temporary; it's a value-add service, but not the primary driver of valuation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\nThe strategic shift related to the IVD services and manufacturing capabilities is evidenced by the deconsolidation of the Veracyte SAS entity, which included these operations.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImpairment Charge on Related Assets (Q2 2025)\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharmaceutical and Other Revenue\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharmaceutical and Other Revenue Year-over-Year Growth\u003c\/td\u003e\n\u003ctd\u003eQ2 2025 vs Q2 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharmaceutical and Other Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharmaceutical and Other Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nThe sale of the manufacturing operations of Veracyte SAS to Helio Diagnostics SAS closed on \u003cstrong\u003eAugust 1, 2025\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nThe financial impact of the restructuring and liquidation proceedings of Veracyte SAS on GAAP Net Income was:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Loss from deconsolidation: \u003cstrong\u003e$6.7 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eVeracyte, Inc. (VCYT) - VRIO Analysis: \u003cstrong\u003e9. Operational Execution and Guidance Credibility\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The ability to consistently meet or beat expectations and raise full-year guidance builds investor confidence.\u003c\/p\u003e\n\u003cp\u003eThe company raised full-year 2025 testing revenue guidance to \u003cstrong\u003e$484 million to $487 million\u003c\/strong\u003e, representing 16% year-over-year growth, up from prior guidance of $477 million to $483 million. Total revenue guidance for 2025 was also raised to $506 million to $510 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; in the complex diagnostics world, consistent execution is surprisingly rare.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Very difficult; this stems from management skill, accurate forecasting, and tight operational control.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Excellent; CEO Marc Stapley noted outstanding Q3 2025 growth and margin expansion, leading to guidance increases.\u003c\/p\u003e\n\u003cp\u003eQ3 2025 financial results demonstrated strong operational performance:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal revenue was \u003cstrong\u003e$131.9 million\u003c\/strong\u003e, an increase of 14% compared to Q3 2024.\u003c\/li\u003e\n\u003cli\u003eTesting revenue was \u003cstrong\u003e$127.8 million\u003c\/strong\u003e, up 17% year-over-year.\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA margin reached 30.1% of revenue, compared to 23.6% in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eCash from operations generated was \u003cstrong\u003e$44.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents, and short-term investments ended the quarter at \u003cstrong\u003e$366.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe execution across key product lines contributed to the results:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Value\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDecipher Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$82.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAfirma Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Testing Volume\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e43,679\u003c\/strong\u003e tests\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe full-year 2025 adjusted EBITDA margin guidance was raised to exceed 25% from the previous 23.5%.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; management credibility is a powerful, intangible asset that attracts capital.\u003c\/p\u003e\n\u003cp\u003eThe company raised its full-year 2025 adjusted EBITDA margin guidance to exceed 25%.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516275253397,"sku":"vcyt-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/vcyt-vrio-analysis.png?v=1740228550","url":"https:\/\/dcf-model.com\/pt\/products\/vcyt-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}